Docoh
Loading...

ARWR Arrowhead Pharmaceuticals

APP
Utility
RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use
30 Sep 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression.
Anthony Nicholas, Tao Pei, Zhao Xu, Casi Schienebeck, Zhi-Ming Ding
Filed: 26 Mar 21
GRANT
Utility
Organic compositions to treat HSF1-related diseases
17 Aug 21
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
Filed: 14 May 19
APP
Utility
RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
5 Aug 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents.
Zhen Li, Rui Zhu, So Wong
Filed: 15 Apr 21
GRANT
Utility
5′-cyclo-phosphonate modified nucleotides
3 Aug 21
Zhen Li, Tao Pei, Michael Lawler
Filed: 3 Dec 18
APP
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
29 Jul 21
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 7 Apr 21
GRANT
Utility
Organic compositions to treat APOC3-related diseases
20 Jul 21
The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.
Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
Filed: 6 Feb 19
APP
Utility
Targeting Ligands For Therapeutic Compounds
24 Jun 21
Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo.
David B Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
Filed: 24 Feb 21
APP
Utility
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
17 Jun 21
RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described.
So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
Filed: 19 Feb 21
GRANT
Utility
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
4 May 21
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents.
Zhen Li, Rui Zhu, So Wong
Filed: 13 Sep 18
APP
Utility
Rnai Agents for Hepatitis B Virus Infection
8 Apr 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
Filed: 11 Aug 20
APP
Utility
Integrin Targeting Ligands and Uses Thereof
1 Apr 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
Filed: 26 Apr 19
APP
Utility
Integrin Targeting Ligands and Uses Thereof
11 Mar 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
Filed: 23 Oct 20
APP
Utility
Rnai Therapy for Hepatitis B Virus Infection
25 Feb 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. WOODDELL, David B. ROZEMA, David L. LEWIS, Darren H. WAKEFIELD, Lauren J. ALMEIDA
Filed: 9 Sep 20
GRANT
Utility
Compositions and methods for inhibiting gene expression of Hif2alpha
23 Feb 21
RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described.
So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
Filed: 16 Apr 18
APP
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
16 Dec 20
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 25 Aug 20
GRANT
Reissue
Compositions and methods for inhibiting gene expression of hepatitis B virus
7 Dec 20
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene.
Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John
Filed: 18 Aug 16
GRANT
Utility
Compositions and methods for inhibiting gene expression of factor XII
7 Dec 20
RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described.
Steven B. Kanner, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 2 Jun 19
APP
Utility
Integrin Ligands and Uses Thereof
25 Nov 20
Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
Filed: 30 Oct 18
GRANT
Utility
RNAi therapy for hepatitis B virus infection
19 Oct 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 30 Sep 18
APP
Utility
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
23 Sep 20
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Filed: 30 Jan 20
Patents are sorted by USPTO publication date, most recent first